TY  - JOUR
AU  - Báez-Gutiérrez, Nerea
AU  - Rodríguez-Ramallo, Héctor
AU  - Moreno, María Antonia-Pérez
AU  - Arboli, Eduardo-Rodriguez
AU  - Abdel-Kader Martín, Laila
PY  - 2021
DO  - 10.1177/20406207211040335
SN  - 2040-6207
UR  - https://hdl.handle.net/10668/27472
T2  - Therapeutic advances in hematology
AB  - In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine). This combination...
LA  - en
KW  - acute myeloid leukaemia
KW  - hypomethylating agent
KW  - refractory
KW  - relapsed
KW  - venetoclax
KW  - young patients
TI  - Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
TY  - research article
VL  - 12
ER  -